A Safety run-in and Phase II Study of Epacadostat in Combination With Radiation Therapy and Avelumab in Patients With Recurrent Gliomas
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 16 Oct 2018
At a glance
- Drugs Avelumab (Primary) ; Bevacizumab (Primary) ; Epacadostat (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions; Therapeutic Use
- 16 Oct 2018 Last checked against ClinicalTrials.gov: US National Institutes of Health record.
- 05 Oct 2018 Planned End Date changed from 31 Aug 2023 to 31 Jan 2024.
- 05 Oct 2018 Planned primary completion date changed from 31 May 2021 to 31 Oct 2021.